CN108576623A - A kind of lotus seeds nut health care noodles and preparation method thereof - Google Patents
A kind of lotus seeds nut health care noodles and preparation method thereof Download PDFInfo
- Publication number
- CN108576623A CN108576623A CN201810245261.8A CN201810245261A CN108576623A CN 108576623 A CN108576623 A CN 108576623A CN 201810245261 A CN201810245261 A CN 201810245261A CN 108576623 A CN108576623 A CN 108576623A
- Authority
- CN
- China
- Prior art keywords
- parts
- millet
- powder
- lotus
- nut
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 63
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 63
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 63
- 235000012149 noodles Nutrition 0.000 title claims abstract description 50
- 230000036541 health Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 57
- 244000062793 Sorghum vulgare Species 0.000 claims abstract description 44
- 235000019713 millet Nutrition 0.000 claims abstract description 44
- 235000013312 flour Nutrition 0.000 claims abstract description 31
- 108010068370 Glutens Proteins 0.000 claims abstract description 14
- 239000003513 alkali Substances 0.000 claims abstract description 14
- 235000021312 gluten Nutrition 0.000 claims abstract description 14
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 14
- 229920002907 Guar gum Polymers 0.000 claims abstract description 13
- 239000000665 guar gum Substances 0.000 claims abstract description 13
- 235000010417 guar gum Nutrition 0.000 claims abstract description 13
- 229960002154 guar gum Drugs 0.000 claims abstract description 13
- 235000014571 nuts Nutrition 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 240000007087 Apium graveolens Species 0.000 claims description 23
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 23
- 235000010591 Appio Nutrition 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 17
- 241000209140 Triticum Species 0.000 claims description 16
- 235000021307 Triticum Nutrition 0.000 claims description 16
- 244000105624 Arachis hypogaea Species 0.000 claims description 14
- 235000020232 peanut Nutrition 0.000 claims description 14
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 11
- 235000020234 walnut Nutrition 0.000 claims description 11
- 241000758791 Juglandaceae Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000002075 main ingredient Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 5
- 241000208966 Polygala Species 0.000 claims description 5
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 5
- 235000009120 camo Nutrition 0.000 claims description 5
- 235000005607 chanvre indien Nutrition 0.000 claims description 5
- 239000011487 hemp Substances 0.000 claims description 5
- 230000035800 maturation Effects 0.000 claims description 4
- 244000000231 Sesamum indicum Species 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000004898 kneading Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 240000007049 Juglans regia Species 0.000 claims description 2
- 235000009496 Juglans regia Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 23
- 206010039966 Senile dementia Diseases 0.000 abstract description 10
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 210000004958 brain cell Anatomy 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 4
- 239000011707 mineral Substances 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000015654 memory Effects 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract description 2
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000001537 neural effect Effects 0.000 abstract description 2
- 230000032677 cell aging Effects 0.000 abstract 1
- 230000001934 delay Effects 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 229940100445 wheat starch Drugs 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 241000207961 Sesamum Species 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 102000003914 Cholinesterases Human genes 0.000 description 7
- 108090000322 Cholinesterases Proteins 0.000 description 7
- 229940048961 cholinesterase Drugs 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 240000006499 Flammulina velutipes Species 0.000 description 1
- 235000016640 Flammulina velutipes Nutrition 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002186 septum of brain Anatomy 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 235000019465 surimi Nutrition 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/109—Types of pasta, e.g. macaroni or noodles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B2/00—Preservation of foods or foodstuffs, in general
- A23B2/30—Preservation of foods or foodstuffs, in general by heating materials in packages which are not progressively transported through the apparatus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
技术领域technical field
本发明涉及食品加工技术领域,具体涉及一种莲子坚果养生保健面条及其制备方法。The invention relates to the technical field of food processing, in particular to lotus nut health-preserving noodles and a preparation method thereof.
背景技术Background technique
阿尔茨海默病(Alzheimer disease,AD),又叫老年性痴呆,是一种起病隐匿的进行性发展的神经系统退行性疾病,是老年期痴呆最常见的一种类型。临床上以记忆障碍、失语、失用、失认、视空间技能损害、执行功能障碍以及人格和行为改变等全面性痴呆表现为特征,主要表现为渐进性记忆障碍、认知功能障碍、人格改变及语言障碍等神经精神症状,严重影响社交、职业与生活功能。AD的病因及发病机制尚未阐明,特征性病理改变为β淀粉样蛋白沉积形成的细胞外老年斑和tau蛋白过度磷酸化形成的神经细胞内神经原纤维缠结,以及神经元丢失伴胶质细胞增生等。Alzheimer's disease (AD), also known as senile dementia, is a neurodegenerative disease with insidious onset and progressive development, and is the most common type of senile dementia. Clinically, it is characterized by comprehensive dementia such as memory impairment, aphasia, apraxia, agnosia, impairment of visuospatial skills, executive dysfunction, and personality and behavior changes, mainly manifested as progressive memory impairment, cognitive dysfunction, and personality changes Neuropsychiatric symptoms such as speech impairment and language impairment seriously affect social, occupational and life functions. The etiology and pathogenesis of AD have not yet been elucidated, and the characteristic pathological changes are extracellular senile plaques formed by the deposition of β-amyloid protein, neurofibrillary tangles formed by hyperphosphorylation of tau protein, and neuron loss with glial cell proliferation Wait.
目前我国老龄人口越来越来多,患有老年性痴呆症的可能性也在增大,而目前对于老年性痴呆症的治疗主要有安眠药、抗精神病药、抗抑郁、抗癫痫药及神经元保护剂等,最突出的抗乙酰胆碱分解酵素,其对老年性痴呆症仅有改善效果,且效果甚微,需长期治疗,长期的药物治疗不仅会使患者对药物产生依赖性,还有可能损害患者的身体健康,且昂贵的医药费用也增加了患者及其家庭的经济负担。饮食治疗及预防是一种安全有效的治疗方法,在市面上针对中老年人食用的面条较少,中国专利《一种鱿鱼海藻面条及其制备方法》(专利申请号:CN201210281198.6)公开了一种以鱿鱼鱼糜和海藻为主要原料制备的,具有营养保健作用,适用于老年小孩食用的面条,中国专利《一种营养面条及其制备方法》(专利申请号:CN201410403325.4)公开了一种以金针菇为主要原料,添加中药粉及其他添加剂制备的面条,具有良好的保健作用,以上专利均为针对老年人的老年性痴呆症提出改善。At present, the elderly population in my country is increasing, and the possibility of suffering from senile dementia is also increasing. At present, the treatment of senile dementia mainly includes sleeping pills, antipsychotic drugs, antidepressants, antiepileptic drugs and neuronal dementia. Protective agent, etc., the most prominent anti-acetylcholine decomposing enzyme, it only has improvement effect on senile dementia, and the effect is very little, long-term treatment is needed, long-term drug treatment will not only make patients dependent on drugs, but may also damage the The health of the patient, and expensive medical expenses have also increased the economic burden of the patient and his family. Diet therapy and prevention are a safe and effective treatment method. There are few noodles for middle-aged and elderly people on the market. The Chinese patent "A squid seaweed noodle and its preparation method" (patent application number: CN201210281198.6) discloses A kind of noodle prepared with squid surimi and seaweed as the main raw materials, which has the effect of nutrition and health care, and is suitable for eating by elderly children. The Chinese patent "Nutritious Noodles and Its Preparation Method" (patent application number: CN201410403325.4) discloses A kind of noodle prepared by using Flammulina velutipes as main raw material, adding traditional Chinese medicine powder and other additives, has good health care effect, and the above patents are all proposed to improve the senile dementia of the elderly.
发明内容Contents of the invention
为了解决上述问题,本发明提供了一种莲子坚果养生保健面条及其制备方法,该面条营养丰富,富含氨基酸、维生素和矿物质等营养物质,不仅能提高机体的抗氧化活性,增强免疫力,还能够对神经中枢方面具有一定的保健作用,能够维持神经中枢的学习记忆能力,延缓脑细胞衰老,从而有效防治老年痴呆疾病的发生。In order to solve the above problems, the present invention provides a lotus nut health care noodle and its preparation method. The noodle is rich in nutrition, rich in amino acids, vitamins, minerals and other nutrients, which can not only improve the antioxidant activity of the body, but also enhance immunity , can also have a certain health care effect on the nerve center, can maintain the learning and memory ability of the nerve center, delay the aging of brain cells, and thus effectively prevent and treat the occurrence of senile dementia.
本发明通过以下技术方案来实现:The present invention is realized through the following technical solutions:
一种莲子坚果养生保健面条,由以下重量份的原材料组成:中药煎剂15-20份、芹菜提取物0.8-1.2份、复合坚果粉7-9份、黄原胶0.25-0.35份、瓜尔豆胶0.08-0.12份、谷朊粉4.6-5.4份、食用碱0.18-0.22份、小米粉8-12份、莲子粉4-6份、小麦粉至100份。A lotus nut health care noodle, which is composed of the following raw materials in parts by weight: 15-20 parts of traditional Chinese medicine decoction, 0.8-1.2 parts of celery extract, 7-9 parts of compound nut powder, 0.25-0.35 parts of xanthan gum, guar 0.08-0.12 parts of bean gum, 4.6-5.4 parts of gluten powder, 0.18-0.22 parts of edible alkali, 8-12 parts of millet flour, 4-6 parts of lotus seed powder, and up to 100 parts of wheat flour.
优选地,一种莲子坚果养生保健面条,由以下重量份的原材料组成:中药煎剂17.5份、芹菜提取物1份、复合坚果粉8份、黄原胶0.3份、瓜尔豆胶0.1份、谷朊粉5份、食用碱0.2份、小米粉10份、莲子粉5份、小麦粉至100份。Preferably, a lotus nut health care noodle is composed of the following raw materials in parts by weight: 17.5 parts of traditional Chinese medicine decoction, 1 part of celery extract, 8 parts of compound nut powder, 0.3 parts of xanthan gum, 0.1 part of guar gum, 5 parts of gluten powder, 0.2 parts of edible alkali, 10 parts of millet flour, 5 parts of lotus seed powder, and up to 100 parts of wheat flour.
优选地,所述的中药煎剂的制备方法为:分别将等量的地黄、火麻仁、远志粉碎过40目筛,混合均匀,加入10倍量煎煮3次,每次2h,过滤,合并3次煎液,用0.2μm微孔滤膜过滤,浓缩至原滤液的1/3,得到中药煎剂。Preferably, the preparation method of the traditional Chinese medicine decoction is as follows: respectively crush the same amount of rehmannia glutinosa, hemp seed, and polygala through a 40-mesh sieve, mix evenly, add 10 times the amount and decoct 3 times, each time for 2 hours, filter, The three decoctions were combined, filtered with a 0.2 μm microporous membrane, and concentrated to 1/3 of the original filtrate to obtain a traditional Chinese medicine decoction.
优选地,所述的芹菜提取物的制备方法为:取新鲜芹菜,取叶,洗净后干燥粉碎至80目,按料液比1:15加入81%乙醇溶液,在温度为57℃下提取3h,提取结束后过滤,取滤液,干燥,得芹菜提取物。Preferably, the preparation method of the celery extract is as follows: take fresh celery, take leaves, wash, dry and pulverize to 80 mesh, add 81% ethanol solution according to the ratio of solid to liquid at 1:15, and extract at a temperature of 57°C After 3 hours, filter after the extraction, take the filtrate, and dry to obtain the celery extract.
优选地,所述的复合坚果粉由以下重量份的原材料组成:核桃1-2份、芝麻3-4份、花生6-8份;所述的复合坚果粉的制备方法为:将核桃、芝麻、花生分别粉碎过100目筛,按重量份混合均匀,得复合坚果粉。Preferably, the compound nut powder is composed of the following raw materials in parts by weight: 1-2 parts of walnuts, 3-4 parts of sesame, and 6-8 parts of peanuts; the preparation method of the compound nut powder is as follows: walnuts, sesame and peanuts were respectively pulverized through a 100-mesh sieve, mixed uniformly by weight to obtain compound nut powder.
本发明还提供一种莲子坚果养生保健面条的制备方法,包括以下步骤:The present invention also provides a preparation method of lotus nut health care noodles, comprising the following steps:
(1)辅料预处理:将中药煎剂加热至40-50℃,将芹菜提取物加入到中药煎剂中,充分搅拌混合,得辅料混合物;(1) Excipient pretreatment: heating the Chinese medicine decoction to 40-50°C, adding celery extract into the Chinese medicine decoction, stirring and mixing thoroughly to obtain the auxiliary material mixture;
(2)主料预处理:复合坚果粉、黄原胶、瓜尔豆胶、谷朊粉、食用碱、小米粉、莲子粉加入小麦粉中,充分混匀,得主料混合物;(2) Main ingredient pretreatment: compound nut powder, xanthan gum, guar gum, gluten powder, edible alkali, millet flour, lotus seed powder are added to wheat flour, fully mixed, and the main ingredient mixture is obtained;
(3)和面:将步骤(1)所得的辅料混合物和步骤(2)所得的主料混合物混合均匀后,加入水至湿度为35-45%,置于和面机中搅拌15-25min,得莲子小米面团;(3) Kneading dough: After mixing the auxiliary material mixture obtained in step (1) and the main material mixture obtained in step (2) evenly, add water until the humidity is 35-45%, place it in a dough mixing machine and stir for 15-25min, get lotus seed millet dough;
(4)熟化:将步骤(3)所得的莲子小米面团在室温下静置15-20min,得熟化莲子小米面团;(4) maturation: the lotus seed millet dough of step (3) gained is left standstill 15-20min at room temperature, obtains maturation lotus seed millet dough;
(5)压片、切条:将步骤(4)所得的熟化莲子小米面团在压面机中压轧成片状,厚度为1-1.2mm且表面光滑的面片,得莲子小米面片;将莲子小米面片切条成粗细为2.5-3mm的面条,得莲子小米湿面切条;(5) sheeting and strip cutting: the ripened lotus seed and millet dough obtained in step (4) is rolled into flakes in a noodle press, and the thickness is 1-1.2mm and the surface is smooth, so as to obtain the lotus seed and millet dough; Cut the lotus seed and millet noodles into strips with a thickness of 2.5-3mm to get the lotus seed and millet wet noodles;
(6)将步骤(5)所得的莲子小米湿面切条在常温下干燥至面条水分含量为5-6.5%,切断后包装,得成品莲子小米养生保健面条。(6) Dry the cut strips of lotus seed millet wet noodles obtained in step (5) at room temperature until the water content of the noodles is 5-6.5%, cut and pack, to obtain finished lotus seed millet health care noodles.
本发明所述各主要功效成分作用机理如下:The mechanism of action of each main functional component described in the present invention is as follows:
莲子作为药食兼用资源,其营养价值非常高,含有丰富的蛋白质、脂肪、碳水化合物和微量元素等。小米营养全面、丰富,富含维生素B1、B2等,脂肪含量高于大米、小麦等,其蛋白质质量较高,必需氨基酸总量均高于大米、小麦粉、玉米。As a resource for both medicine and food, lotus seeds have very high nutritional value and are rich in protein, fat, carbohydrates and trace elements. Millet is comprehensive and rich in nutrition, rich in vitamins B1 and B2, etc. Its fat content is higher than that of rice and wheat, its protein quality is higher, and its total amount of essential amino acids is higher than that of rice, wheat flour and corn.
地黄能有效控制乙酰胆碱酯酶的活性,调节神经肽的代谢、神经元的发育以及神经的再生功能,延缓神经元的衰老和死亡,从而保持中枢胆碱能系统的正常运行,抑制和预防老年痴呆疾病的发生。Rehmannia glutinosa can effectively control the activity of acetylcholinesterase, regulate the metabolism of neuropeptides, the development of neurons and the regeneration of nerves, delay the aging and death of neurons, thereby maintaining the normal operation of the central cholinergic system, inhibiting and preventing senile dementia the occurrence of disease.
火麻仁中含有丰富的生物活性物质,其中火麻仁油具有显著降低脑组织中的NO含量及脂质代谢产物MDA的水平的功能,能显著提高脑组织中SOD、GSH-Px的水平,抑制脑退化过程,并通过增强机体的抗氧化能力来抗衰老。Hemp seed is rich in bioactive substances, among which hemp seed oil has the function of significantly reducing the NO content in brain tissue and the level of lipid metabolite MDA, and can significantly increase the level of SOD and GSH-Px in brain tissue. Inhibit the brain degenerative process and anti-aging by enhancing the body's antioxidant capacity.
远志具有多种生物活性成分,能够激活和增强UPP的功能,提升UPP途径识别与结合异常集聚蛋白的能力,达到清除脑内有害代谢废物的效果,保护神经元结构与功能的完整性,从而恢复神经细胞的活力,抑制学习记忆障碍的发生,有效防治老年痴呆。Polygala has a variety of biologically active ingredients, which can activate and enhance the function of UPP, improve the ability of UPP pathway to recognize and bind abnormal agglutinin, achieve the effect of removing harmful metabolic waste in the brain, protect the integrity of neuron structure and function, and restore The vitality of nerve cells can inhibit the occurrence of learning and memory disorders, and effectively prevent and treat Alzheimer's disease.
芹菜中含有丰富的黄酮类生物活性物质,其中芹黄素是最主要的黄酮类活性物质,能够提高学习能力和神经的正确反应率,显著提高短期记忆能力、信号方位辨别能力和记忆的保持能力,具有改善老年痴呆疾病的显著效果。Celery is rich in flavonoid bioactive substances, among which apigenin is the most important flavonoid active substance, which can improve learning ability and correct response rate of nerves, and significantly improve short-term memory ability, signal direction discrimination ability and memory retention ability , has the remarkable effect of improving senile dementia.
芝麻在人体生化代谢中能够合成与积累许多次生物质,这些物质的生物活性相当活跃,其中卵磷脂不仅含量丰富,而且乳化性能良好,有利于降低高血压,减少胆固醇,增强血管弹性,抑制血凝,改善血液供养,促进脑部供养供血;这些次生物质还能参与乙酰胆碱的合成转化,加快大脑信息传导速度,增强记忆力,对老年痴呆疾病的预防具有显著效果。Sesame can synthesize and accumulate many secondary biomass in the biochemical metabolism of the human body. The biological activity of these substances is quite active. Among them, lecithin is not only rich in content, but also has good emulsifying performance, which is beneficial to reduce high blood pressure, reduce cholesterol, enhance blood vessel elasticity, and inhibit blood pressure. Coagulate, improve blood supply, and promote blood supply to the brain; these secondary substances can also participate in the synthesis and transformation of acetylcholine, speed up the speed of brain information transmission, enhance memory, and have a significant effect on the prevention of Alzheimer's disease.
核桃中含有丰富的谷氨酸,可使人体合成脑组织中最重要的神经递质γ-氨基丁酸,它是中枢神经系统的抑制性神经递质,可以阻止与焦虑相关的信息抵达脑指示中枢,从而治疗神经精神疾病,如焦虑、神经衰弱等,帮助大脑神经中枢能够保持放松状态,对神经系统具有镇静和调节作用,并能够改善认知和运动性能,提高学习和记忆功能,有效发挥益智和增强记忆力的功能。Walnuts are rich in glutamic acid, which enables the body to synthesize the most important neurotransmitter in brain tissue, γ-aminobutyric acid. It is an inhibitory neurotransmitter in the central nervous system, which can prevent information related to anxiety from reaching the brain instructions Center, so as to treat neuropsychiatric diseases, such as anxiety, neurasthenia, etc., help the brain nerve center to maintain a relaxed state, have a calming and regulating effect on the nervous system, and can improve cognitive and motor performance, improve learning and memory functions, and effectively exert Puzzle and memory enhancing functions.
花生中的赖氨酸能够提高智力,谷氨酸和天门冬氨酸可促进神经细胞的活力和增强大脑的记忆能力,花生中含有的锌等矿物质具有激活中老年人脑细胞的作用,此外,花生中含量丰富的脂溶性维生素K、卵磷脂、脑磷脂能够延缓大脑功能衰退;花生中所含有的儿茶素也对人体具有很强的抗衰老作用。Lysine in peanuts can improve intelligence, glutamic acid and aspartic acid can promote the vitality of nerve cells and enhance the memory ability of the brain, zinc and other minerals contained in peanuts can activate the brain cells of middle-aged and elderly people. , the fat-soluble vitamin K, lecithin, and cephalin rich in peanuts can delay the decline of brain function; the catechin contained in peanuts also has a strong anti-aging effect on the human body.
本发明具备以下有益效果:The present invention has the following beneficial effects:
本发明将小米粉、莲子粉添加到小麦粉中,能够通过合理的营养互补,解决谷物食品中必需氨基酸不均衡的问题,更能赋予谷物产品以小米、莲子的特殊保健功能,使面条易于被人体吸收,促进消化。The invention adds millet flour and lotus seed flour to wheat flour, which can solve the problem of unbalanced essential amino acids in cereal foods through reasonable nutritional complementarity, and can endow cereal products with special health care functions of millet and lotus seeds, making noodles easy to be consumed by the human body. Absorption, promote digestion.
本发明将地黄、火麻仁、远志进行配伍制作复合煎液加入到面条中,能够从促进神经元活性、消除神经中枢的障碍以及提高神经中枢抗氧化能力多靶点、全方位保护神经元的活力,维持神经中枢的学习记忆能力,延缓脑细胞衰老进程,防治老年痴呆疾病的发生。In the present invention, rehmannia glutinosa, hemp seed, and polygala are combined to make a compound decoction and added to the noodles, which can promote the activity of neurons, eliminate the obstacles of the nerve center, improve the anti-oxidation ability of the nerve center, and protect neurons in an all-round way. Vitality, maintain the learning and memory ability of the nerve center, delay the aging process of brain cells, and prevent the occurrence of Alzheimer's disease.
本发明将芝麻、花生、核桃复配后作为复合坚果粉加入面条中,其营养成分互补配合,能够为人体提供全面而充足的氨基酸、维生素和矿物质,帮助延缓人体老化以及激活衰老脑细胞和增加神经细胞活性,有效防治老年痴呆疾病的发生。In the present invention, sesame, peanuts and walnuts are compounded and added to the noodles as compound nut powder. The nutritional components are complementary and can provide the human body with comprehensive and sufficient amino acids, vitamins and minerals, helping to delay the aging of the human body and activate aging brain cells and Increase the activity of nerve cells and effectively prevent the occurrence of Alzheimer's disease.
具体实施方式Detailed ways
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施例,进一步阐述本发明。In order to make the technical means, creative features, goals and effects achieved by the present invention easy to understand, the present invention will be further described below in conjunction with specific embodiments.
实施例1Example 1
一种莲子坚果养生保健面条,由以下重量份的原材料组成:中药煎剂15份、芹菜提取物0.8份、复合坚果粉7份、黄原胶0.25份、瓜尔豆胶0.08份、谷朊粉4.6份、食用碱0.18份、小米粉8份、莲子粉4份、小麦粉60.09份。A lotus nut health care noodle, which is composed of the following raw materials in parts by weight: 15 parts of traditional Chinese medicine decoction, 0.8 part of celery extract, 7 parts of compound nut powder, 0.25 part of xanthan gum, 0.08 part of guar gum, gluten powder 4.6 parts, 0.18 parts of edible alkali, 8 parts of millet flour, 4 parts of lotus seed powder, and 60.09 parts of wheat flour.
所述的中药煎剂的制备方法为:分别将等量的地黄、火麻仁、远志粉碎过40目筛,混合均匀,加入10倍量煎煮3次,每次2h,过滤,合并3次煎液,用0.2μm微孔滤膜过滤,浓缩至原滤液的1/3,得到中药煎剂。The preparation method of the traditional Chinese medicine decoction is as follows: respectively crush the same amount of rehmannia glutinosa, hemp seed, and polygala through a 40-mesh sieve, mix evenly, add 10 times the amount to decoct 3 times, each time for 2 hours, filter, and combine 3 times The decoction is filtered with a 0.2 μm microporous membrane, and concentrated to 1/3 of the original filtrate to obtain a traditional Chinese medicine decoction.
所述的芹菜提取物的制备方法为:取新鲜芹菜,取叶,洗净后干燥粉碎至80目,按料液比1:15加入81%乙醇溶液,在温度为57℃下提取3h,提取结束后过滤,取滤液,干燥,得芹菜提取物。The preparation method of the celery extract is as follows: take fresh celery, take leaves, wash, dry and pulverize to 80 mesh, add 81% ethanol solution according to the ratio of solid to liquid at 1:15, extract at a temperature of 57°C for 3 hours, extract After finishing, filter, take the filtrate, and dry to obtain celery extract.
所述的复合坚果粉由以下重量份的原材料组成:核桃1份、芝麻3份、花生6份;所述的复合坚果粉的制备方法为:将核桃、芝麻、花生分别粉碎过100目筛,按重量份混合均匀,得复合坚果粉。The composite nut powder is composed of the following raw materials in parts by weight: 1 part of walnut, 3 parts of sesame, and 6 parts of peanut; Mix evenly according to parts by weight to obtain compound nut powder.
上述一种莲子坚果养生保健面条的制备方法,包括以下步骤:The preparation method of the above-mentioned lotus nut health care noodles comprises the following steps:
(1)辅料预处理:将中药煎剂加热至45℃,将芹菜提取物加入到中药煎剂中,充分搅拌混合,得辅料混合物;(1) Excipient pretreatment: heating the Chinese medicine decoction to 45°C, adding celery extract into the Chinese medicine decoction, stirring and mixing thoroughly to obtain the auxiliary material mixture;
(2)主料预处理:复合坚果粉、黄原胶、瓜尔豆胶、谷朊粉、食用碱、小米粉、莲子粉加入小麦粉中,充分混匀,得主料混合物;(2) Main ingredient pretreatment: compound nut powder, xanthan gum, guar gum, gluten powder, edible alkali, millet flour, lotus seed powder are added to wheat flour, fully mixed, and the main ingredient mixture is obtained;
(3)和面:将步骤(1)所得的辅料混合物和步骤(2)所得的主料混合物混合均匀后,加入水至湿度为40%,置于和面机中搅拌20min,得莲子小米面团;(3) Kneading dough: After mixing the auxiliary material mixture obtained in step (1) and the main material mixture obtained in step (2) evenly, add water until the humidity is 40%, place it in a dough mixer and stir for 20 minutes to obtain lotus seed millet dough ;
(4)熟化:将步骤(3)所得的莲子小米面团在室温下静置17.5min,得熟化莲子小米面团;(4) aging: the lotus seed and millet dough obtained in step (3) was left to stand at room temperature for 17.5 minutes to obtain the ripened lotus seed and millet dough;
(5)压片、切条:将步骤(4)所得的熟化莲子小米面团在压面机中压轧成片状,厚度为1.1mm且表面光滑的面片,得莲子小米面片;将莲子小米面片切条成粗细为2.75mm的面条,得莲子小米湿面切条;(5) Sheeting and strip cutting: the ripened lotus seed and millet dough obtained in step (4) is rolled into a sheet in a noodle press, and the thickness is 1.1mm and the surface is smooth, so as to obtain the lotus seed and millet dough; Cut the millet noodles into strips with a thickness of 2.75mm, and cut the lotus seed millet wet noodles into strips;
(6)将步骤(5)所得的莲子小米湿面切条在常温下干燥至面条水分含量为5.75%,切断后包装,得成品莲子小米养生保健面条。(6) Dry the strips of wet noodles with lotus seeds and millet obtained in step (5) at room temperature until the water content of the noodles is 5.75%, cut them and pack them to obtain finished lotus seeds and millet health care noodles.
实施例2Example 2
一种莲子坚果养生保健面条,由以下重量份的原材料组成:中药煎剂17.5份、芹菜提取物1份、复合坚果粉8份、黄原胶0.3份、瓜尔豆胶0.1份、谷朊粉5份、食用碱0.2份、小米粉10份、莲子粉5份、小麦粉52.9份。A lotus nut health care noodle, which is composed of the following raw materials in parts by weight: 17.5 parts of Chinese medicine decoction, 1 part of celery extract, 8 parts of compound nut powder, 0.3 part of xanthan gum, 0.1 part of guar gum, gluten powder 5 parts, 0.2 parts of edible alkali, 10 parts of millet flour, 5 parts of lotus seed powder, and 52.9 parts of wheat flour.
所述的复合坚果粉由以下重量份的原材料组成:核桃1.5份、芝麻3.5份、花生7份;所述的复合坚果粉的制备方法为:将核桃、芝麻、花生分别粉碎过100目筛,按重量份混合均匀,得复合坚果粉。The compound nut powder is composed of the following raw materials in parts by weight: 1.5 parts of walnuts, 3.5 parts of sesame, and 7 parts of peanuts; the preparation method of the compound nut powder is as follows: respectively crushing walnuts, sesame and peanuts through a 100-mesh sieve, Mix evenly according to parts by weight to obtain compound nut powder.
实施例3Example 3
一种莲子坚果养生保健面条,由以下重量份的原材料组成:中药煎剂20份、芹菜提取物1.2份、复合坚果粉9份、黄原胶0.35份、瓜尔豆胶0.12份、谷朊粉5.4份、食用碱0.22份、小米粉12份、莲子粉6份、小麦粉45.71份。A lotus nut health care noodle, which is composed of the following raw materials in parts by weight: 20 parts of traditional Chinese medicine decoction, 1.2 parts of celery extract, 9 parts of compound nut powder, 0.35 parts of xanthan gum, 0.12 parts of guar gum, gluten powder 5.4 parts, 0.22 parts of edible alkali, 12 parts of millet flour, 6 parts of lotus seed powder, and 45.71 parts of wheat flour.
所述的复合坚果粉由以下重量份的原材料组成:核桃2份、芝麻4份、花生8份;所述的复合坚果粉的制备方法为:将核桃、芝麻、花生分别粉碎过100目筛,按重量份混合均匀,得复合坚果粉。The compound nut powder is composed of the following raw materials in parts by weight: 2 parts of walnuts, 4 parts of sesame, and 8 parts of peanuts; the preparation method of the compound nut powder is as follows: respectively crushing walnuts, sesame and peanuts through a 100-mesh sieve, Mix evenly according to parts by weight to obtain compound nut powder.
对比例1Comparative example 1
与实施例1的区别在于,原料配方中没有添加中药煎剂,具体为:芹菜提取物1份、复合坚果粉8份、黄原胶0.3份、瓜尔豆胶0.1份、谷朊粉5份、食用碱0.2份、小米粉10份、莲子粉5份、小麦粉70.4份。The difference from Example 1 is that no traditional Chinese medicine decoction is added to the raw material formula, specifically: 1 part of celery extract, 8 parts of compound nut powder, 0.3 part of xanthan gum, 0.1 part of guar gum, and 5 parts of gluten powder , 0.2 parts of edible alkali, 10 parts of millet flour, 5 parts of lotus seed powder, and 70.4 parts of wheat flour.
对比例2Comparative example 2
与实施例1的区别在于,原料配方中没有添加芹菜提取物,具体为:中药煎剂17.5份、复合坚果粉8份、黄原胶0.3份、瓜尔豆胶0.1份、谷朊粉5份、食用碱0.2份、小米粉10份、莲子粉5份、小麦粉53.9份。The difference from Example 1 is that no celery extract is added to the raw material formula, specifically: 17.5 parts of Chinese medicine decoction, 8 parts of compound nut powder, 0.3 part of xanthan gum, 0.1 part of guar gum, and 5 parts of gluten powder , 0.2 parts of edible alkali, 10 parts of millet flour, 5 parts of lotus seed powder, and 53.9 parts of wheat flour.
对比例3Comparative example 3
与实施例1的区别在于,原料配方中没有添加复合坚果粉,具体为:中药煎剂17.5份、芹菜提取物1份、黄原胶0.3份、瓜尔豆胶0.1份、谷朊粉5份、食用碱0.2份、小米粉10份、莲子粉5份、小麦粉61.9份。The difference from Example 1 is that no compound nut powder is added to the raw material formula, specifically: 17.5 parts of Chinese medicine decoction, 1 part of celery extract, 0.3 part of xanthan gum, 0.1 part of guar gum, and 5 parts of gluten powder , 0.2 parts of edible alkali, 10 parts of millet flour, 5 parts of lotus seed powder, and 61.9 parts of wheat flour.
功效验证Efficacy verification
试验例1Test example 1
取12月龄,体重30g左右的小鼠80只,雌雄各半,随机分成8组,取其中一组作为空白对照组,每日注射生理盐水,另外7组小鼠每日注射D-半乳糖+亚硝酸钠,连续2个月,建立痴呆模型组,取一组作为模型组,另外6组作为实验组,每日喂饲实施例1-3和对比例1-3制成的面条,连续喂饲4周,按胆碱酯酶(AchE)试剂盒严格操作,测定皮层及海马区胆碱酯酶活性,其结果如表1所示:Take 80 12-month-old mice with a body weight of about 30g, half male and half male, and randomly divide them into 8 groups, one of which is used as the blank control group, injected with normal saline every day, and the other 7 groups of mice are injected with D-galactose every day +sodium nitrite, for 2 consecutive months, to establish a dementia model group, get one group as the model group, and another 6 groups as the experimental group, feeding the noodles made by Example 1-3 and Comparative Example 1-3 every day, continuously Feed for 4 weeks, operate strictly according to cholinesterase (AchE) kit, measure the cholinesterase activity of cortex and hippocampus, its result is as shown in table 1:
表1各组小鼠部分脑区胆碱酯酶活性Table 1 Cholinesterase activity in some brain regions of mice in each group
胆碱能系统功能缺陷与AD密切相关,AD脑内隔区等部位的胆碱能神经元明显减少,Ach作为促进学习以及的递质,可通过检测AchE的活性来说明本发明制备的面条对胆碱能神经功能低下的改善作用。由表1可知,模型组的胆碱酯酶活性明显高于空白对照组,而实施例1-3和对比例1-3均能降低模型组的胆碱酯酶活性,相对而言,实施例1-3对降低胆碱酯酶活性具有显著的差异性,表明本发明制备的莲子坚果养生保健面条能通过抑制AchE的活性,减少Ach的水解来达到防治AD的效果。The cholinergic system functional defect is closely related to AD, and the cholinergic neurons at positions such as septal areas in the AD brain are significantly reduced, and Ach, as a transmitter for promoting learning and learning, can be illustrated by detecting the activity of AchE. Improvement of cholinergic hypofunction. As can be seen from Table 1, the cholinesterase activity of the model group is significantly higher than that of the blank control group, and examples 1-3 and comparative examples 1-3 can all reduce the cholinesterase activity of the model group, relatively speaking, the examples 1-3 1-3 have significant differences in reducing the activity of cholinesterase, indicating that the lotus nut health care noodles prepared by the present invention can prevent and treat AD by inhibiting the activity of AchE and reducing the hydrolysis of Ach.
试验例2Test example 2
取12月龄,体重30g左右的小鼠80只,雌雄各半,随机分成8组,取其中一组作为空白对照组,每日注射生理盐水,另外7组小鼠每日注射D-半乳糖+亚硝酸钠,连续2个月,建立痴呆模型组,取一组作为模型组,另外6组作为实验组,每日喂饲实施例1-3和对比例1-3制成的面条,连续喂饲4周,将个小鼠进行水迷宫实验,在安全台上停留超过2s为成功,每天训练2次,共4天,从入睡到到达安全台的时间为逃避潜伏期,记录小鼠游泳轨迹,其结果如表2所示:Take 80 12-month-old mice with a body weight of about 30g, half male and half male, and randomly divide them into 8 groups, one of which is used as the blank control group, injected with normal saline every day, and the other 7 groups of mice are injected with D-galactose every day +sodium nitrite, for 2 consecutive months, to establish a dementia model group, get one group as the model group, and another 6 groups as the experimental group, feeding the noodles made by Example 1-3 and Comparative Example 1-3 every day, continuously After feeding for 4 weeks, each mouse was subjected to a water maze experiment. If it stayed on the safety platform for more than 2 seconds, it was considered successful. It was trained twice a day for a total of 4 days. The time from falling asleep to reaching the safety platform was the escape latency period, and the swimming track of the mice was recorded. , and the results are shown in Table 2:
表2各组小鼠水迷宫实验结果Table 2 The results of the water maze experiment on mice in each group
由表2可知,模型组与空白对照组比较,逃避潜伏时间具有显著性的延长,平台跨越次数显著性的减少,而喂食实施例1-3后,模型小鼠的逃避潜伏时间和平台跨越次数得到显著性的改善,对比例1-3虽对模型小鼠的逃避潜伏时间和平台跨越次数有改善,但其效果甚微,且其添加单一成分,营养不够全面,其有效防治AD的效果不佳。As can be seen from Table 2, compared with the blank control group, the escape latency of the model group was significantly prolonged, and the platform crossing times were significantly reduced. After feeding Examples 1-3, the escape latency and platform crossing times of the model mice were significantly reduced. Obtain significant improvement, although comparative example 1-3 improves the escape latency of model mice and the number of platform crossings, its effect is very small, and it adds a single component, and the nutrition is not comprehensive enough, and the effect of its effective prevention and treatment of AD is not enough. good.
实验结束后,断颈处死小鼠,分离脑部组织,制备单细胞悬液,裂解细胞按照放免试剂盒的说明操作检测Aβ的含量,其结果如表3所示:After the experiment, the mice were killed by neck dislocation, the brain tissue was separated, and a single cell suspension was prepared, and the cells were lysed to detect the Aβ content according to the instructions of the radioimmunoassay kit. The results are shown in Table 3:
表3各组小鼠脑组织Aβ表达水平Table 3 The expression levels of Aβ in brain tissue of mice in each group
β淀粉样蛋白(Aβ)的聚集和神经原纤维缠结是AD的主要病理变化,也是老年斑的核心成分,Aβ的聚集可以导致氧自由基的升高、炎症反应、细胞凋亡和神经系统退行性变,因此,抑制Aβ的生成是治疗AD的有效方法。由表3可以看出,模型组的Aβ含量明显高于空白对照组,而实施例1-3能显著降低模型组的Aβ含量,说明本发明制备的莲子坚果养生保健面条能有效治疗AD。The aggregation of β-amyloid protein (Aβ) and neurofibrillary tangles are the main pathological changes of AD and the core components of senile plaques. The aggregation of Aβ can lead to the increase of oxygen free radicals, inflammatory response, apoptosis and nervous system degeneration Therefore, inhibiting the production of Aβ is an effective method for the treatment of AD. As can be seen from Table 3, the Aβ content of the model group is significantly higher than that of the blank control group, while Examples 1-3 can significantly reduce the Aβ content of the model group, indicating that the lotus nut health care noodles prepared by the present invention can effectively treat AD.
综上所述,本发明制备的莲子坚果养生保健面条能抑制胆碱酯酶的活性,降低Aβ的含量,从而能够有效治疗及预防AD。In summary, the lotus nut health care noodles prepared by the present invention can inhibit the activity of cholinesterase and reduce the content of Aβ, thereby effectively treating and preventing AD.
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。The above-mentioned embodiments only express several implementation modes of the present invention, and the description thereof is relatively specific and detailed, but should not be construed as limiting the patent scope of the present invention. It should be pointed out that those skilled in the art can make several modifications and improvements without departing from the concept of the present invention, and these all belong to the protection scope of the present invention.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810245261.8A CN108576623A (en) | 2018-03-23 | 2018-03-23 | A kind of lotus seeds nut health care noodles and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810245261.8A CN108576623A (en) | 2018-03-23 | 2018-03-23 | A kind of lotus seeds nut health care noodles and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108576623A true CN108576623A (en) | 2018-09-28 |
Family
ID=63627326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810245261.8A Pending CN108576623A (en) | 2018-03-23 | 2018-03-23 | A kind of lotus seeds nut health care noodles and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108576623A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709143A (en) * | 2005-06-25 | 2005-12-21 | 王浩贵 | Lotus seed health-care noodles |
CN104027428A (en) * | 2013-03-05 | 2014-09-10 | 刘燎原 | Preparation method of traditional Chinese medicine compound and application in prevention and treatment of Alzheimer disease |
CN106389740A (en) * | 2016-09-13 | 2017-02-15 | 王全峰 | A composition for preventing and/or delaying age-related cognitive impairment and its application method |
CN107212249A (en) * | 2017-04-25 | 2017-09-29 | 孙玉飞 | A kind of Noodles with Vegetables and preparation method thereof |
-
2018
- 2018-03-23 CN CN201810245261.8A patent/CN108576623A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709143A (en) * | 2005-06-25 | 2005-12-21 | 王浩贵 | Lotus seed health-care noodles |
CN104027428A (en) * | 2013-03-05 | 2014-09-10 | 刘燎原 | Preparation method of traditional Chinese medicine compound and application in prevention and treatment of Alzheimer disease |
CN106389740A (en) * | 2016-09-13 | 2017-02-15 | 王全峰 | A composition for preventing and/or delaying age-related cognitive impairment and its application method |
CN107212249A (en) * | 2017-04-25 | 2017-09-29 | 孙玉飞 | A kind of Noodles with Vegetables and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
孙启发: "小米莲子面条中添加剂复配的研究", 《粮食加工》 * |
李杰,等: "基于响应面分析法的芹菜黄酮提取优化工艺研究", 《安徽农业科学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112869162B (en) | Composition with functions of resisting fatigue and improving sleep and preparation method thereof | |
CN105380271B (en) | Additive-free full seed mung bean composite nutrient powder and its production method | |
JP6838745B2 (en) | A method for producing fermented mineral raw food pills that have the function of improving constipation and recovery from fatigue. | |
CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
KR101018065B1 (en) | Health drink manufacturing method using jujube and health drink produced by | |
KR20180024172A (en) | Health food for Weight loss and skin with improved and Manufacturing method | |
CN111902049A (en) | Health beverage composition having excellent hangover alleviating effect and preventing liver damage due to alcohol | |
KR101627837B1 (en) | Health supplement food comprising horse bone extracts as main ingredients and sea horse and manufacturing method for the same | |
CN103478820A (en) | Eucommia male flower beverage | |
KR102131341B1 (en) | The manufacturing method of functional sunsik | |
CN101564180B (en) | Walnut total nutriment and soft capsule and health products containing same | |
CN102972836A (en) | Health care beverage containing eucommia | |
JP2018510641A (en) | Health supplements for hair growth promotion, hair loss relief and improvement, blood sugar control, gastrointestinal symptom relief and improvement | |
CN108095118A (en) | A kind of slimming health food | |
KR20130141237A (en) | Cosmetic composition | |
CN108576623A (en) | A kind of lotus seeds nut health care noodles and preparation method thereof | |
CN106729190B (en) | A granule containing Chinese medicinal effective components for invigorating spleen, invigorating qi and eliminating dampness, and its preparation method | |
CN116268107A (en) | Formula goat milk powder with antidepressant function and preparation method thereof | |
KR20040097813A (en) | Composition containing Diet Neurotrophic Factor having anti-fatness functions | |
KR102480311B1 (en) | The manufacturing method of making healthcare food composition for costitutional group | |
KR101439792B1 (en) | Oriental medicine composition for children's underweight and respiratory organ, and oriental medicine extracts derived therefrom, and method of preparing the same | |
KR101241455B1 (en) | Bean curd having hypotensive effect | |
KR20140038644A (en) | Method for manufacturing allium hookeri pill, and allium hookeri pill produced thereby | |
CN114601919B (en) | An antioxidant and sleep-aid composition and its application | |
KR101485261B1 (en) | Composition for rolling pills comprising adlay and rolling method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180928 |